Alliancebernstein L.P. Sells 85,000 Shares of Prestige Consumer Healthcare Inc. (NYSE:PBH)

Alliancebernstein L.P. trimmed its position in shares of Prestige Consumer Healthcare Inc. (NYSE:PBH - Free Report) by 57.1% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 63,945 shares of the company's stock after selling 85,000 shares during the quarter. Alliancebernstein L.P. owned approximately 0.13% of Prestige Consumer Healthcare worth $4,993,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also recently added to or reduced their stakes in the company. Kestra Investment Management LLC acquired a new position in shares of Prestige Consumer Healthcare in the 4th quarter worth approximately $27,000. CIBC Private Wealth Group LLC boosted its stake in Prestige Consumer Healthcare by 48.9% in the fourth quarter. CIBC Private Wealth Group LLC now owns 463 shares of the company's stock worth $34,000 after purchasing an additional 152 shares in the last quarter. GAMMA Investing LLC increased its stake in shares of Prestige Consumer Healthcare by 18.9% in the fourth quarter. GAMMA Investing LLC now owns 1,383 shares of the company's stock valued at $108,000 after buying an additional 220 shares in the last quarter. Blue Trust Inc. raised its holdings in shares of Prestige Consumer Healthcare by 24.8% in the fourth quarter. Blue Trust Inc. now owns 2,190 shares of the company's stock valued at $158,000 after buying an additional 435 shares during the last quarter. Finally, KBC Group NV lifted its position in Prestige Consumer Healthcare by 28.3% during the 4th quarter. KBC Group NV now owns 2,048 shares of the company's stock worth $160,000 after buying an additional 452 shares in the last quarter. 99.95% of the stock is owned by institutional investors.

Prestige Consumer Healthcare Stock Up 0.4 %

Shares of Prestige Consumer Healthcare stock traded up $0.30 during trading hours on Friday, reaching $80.10. 292,350 shares of the company's stock were exchanged, compared to its average volume of 286,757. The stock has a market cap of $3.97 billion, a P/E ratio of 18.76, a P/E/G ratio of 2.69 and a beta of 0.47. The company has a 50 day moving average of $84.16 and a two-hundred day moving average of $80.09. The company has a current ratio of 3.68, a quick ratio of 2.20 and a debt-to-equity ratio of 0.56. Prestige Consumer Healthcare Inc. has a fifty-two week low of $62.35 and a fifty-two week high of $90.04.

Prestige Consumer Healthcare (NYSE:PBH - Get Free Report) last posted its quarterly earnings results on Thursday, February 6th. The company reported $1.22 earnings per share for the quarter, beating analysts' consensus estimates of $1.18 by $0.04. Prestige Consumer Healthcare had a return on equity of 12.36% and a net margin of 19.13%. On average, sell-side analysts forecast that Prestige Consumer Healthcare Inc. will post 4.5 EPS for the current fiscal year.

Insider Activity

In related news, SVP Mary Beth Fritz sold 1,678 shares of Prestige Consumer Healthcare stock in a transaction dated Monday, March 10th. The stock was sold at an average price of $90.00, for a total transaction of $151,020.00. Following the completion of the transaction, the senior vice president now owns 17,157 shares in the company, valued at approximately $1,544,130. This trade represents a 8.91 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Insiders own 1.60% of the company's stock.

Analyst Ratings Changes

A number of brokerages have weighed in on PBH. Canaccord Genuity Group boosted their target price on shares of Prestige Consumer Healthcare from $93.00 to $100.00 and gave the stock a "buy" rating in a research note on Friday, February 7th. DA Davidson lifted their target price on Prestige Consumer Healthcare from $95.00 to $104.00 and gave the company a "buy" rating in a research note on Friday, February 7th. StockNews.com cut Prestige Consumer Healthcare from a "buy" rating to a "hold" rating in a report on Tuesday, April 8th. Raymond James upgraded shares of Prestige Consumer Healthcare to a "moderate buy" rating in a research report on Thursday, December 19th. Finally, Royal Bank of Canada boosted their price target on shares of Prestige Consumer Healthcare from $96.00 to $97.00 and gave the stock a "sector perform" rating in a research note on Friday, March 21st. Four investment analysts have rated the stock with a hold rating and three have given a buy rating to the company's stock. According to data from MarketBeat, the stock currently has a consensus rating of "Hold" and a consensus target price of $93.33.

Prestige Consumer Healthcare Profile

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.